Cited by 1,149Parkinson's Disease Mechanisms and TreatmentsNeurological diseases and metabolismTrace Elements in Health

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Increased Nigral Iron Content and Alterations in Other Metal Ions Occurring in Brain in Parkinson's Disease

Dexter, D. T., Wells, F. R., Lee, A. J., Agid, F., Agid, Y., Jenner, P., Marsden, C. D.·1989·Journal of Neurochemistry

DOI 10.1111/j.1471-4159.1989.tb07264.x

Open this paper in CoChat — free account

Abstract

Levels of iron, copper, zinc, manganese, and lead were measured by inductively coupled plasma spectroscopy in parkinsonian and age-matched control brain tissue. There was 31-35% increase in the total iron content of the parkinsonian substantia nigra when compared to control tissue. In contrast, in the globus pallidus total iron levels were decreased by 29% in Parkinson's disease. There was no change in the total iron levels in any other region of the parkinsonian brain. Total copper levels were reduced by 34-45% in the substantia nigra in Parkinson's disease; no difference was found in the other brain areas examined. Zinc levels were increased in substantia nigra in Parkinson's disease by 50-54%, and the zinc content of the caudate nucleus and lateral putamen was also raised by 18-35%. Levels of manganese and lead were unchanged in all areas of the parkinsonian brain studied when compared to control brains, except for a small decrease (20%) in manganese content of the medial putamen. Increased levels of total iron in the substantia nigra may cause the excessive formation of toxic oxygen radicals, leading to dopamine cell death.

Integrity signals

Registry

Crossref · 10.1111/j.1471-4159.1989.tb07264.x

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
The effect of age on the non-haemin iron in the human brain
Hallgren, B., & Sourander, P. (1958) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1958.tb12607.x · Cited by 1,427
Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease
Dexter, D. T., Carter, C. J., Wells, F. R., Javoy-Agid, F., Agid, Y., Lees, A. J., Jenner, P. G., & MARSDEN, C. D. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb09133.x · Cited by 1,397
Self-citation
Chronic parkinsonism secondary to intravenous injection of meperidine analogues
Davis, G. C., Williams, A. C., Markey, S. P., Ebert, M. H., Caine, E. D., Reichert, C. M., & Kopin, I. J. (1979) · Psychiatry Research · doi:10.1016/0165-1781(79)90006-4 · Cited by 1,377
FERRITIN: STRUCTURE, GENE REGULATION, AND CELLULAR FUNCTION IN ANIMALS, PLANTS, AND MICROORGANISMS
Theil, E. C. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.001445 · Cited by 1,337
Increased nigral iron content in postmortem parkinsonian brain
Dexter, D. T., Wells, F. R., Agid, F., Agid, Y., Lees, A. J., Jenner, P., & Marsden, C. D. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91361-4 · Cited by 963
Self-citation
Autoxidation versus Covalent Binding of Quinones as the Mechanism of Toxicity of Dopamine, 6-Hydroxydopamine, and Related Compounds toward C1300 Neuroblastoma Cells in Vitro
Graham, D. G., Tiffany, S. M., BELL, W. R., & Gutknecht, W. F. (1978) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13536-0 · Cited by 953
The importance of free radicals and catalytic metal ions in human diseases.
Halliwell, B., & Gutteridge, J. M. C. (1985) · Molecular Aspects of Medicine · doi:10.1016/0098-2997(85)90001-9 · Cited by 941
Iron-Responsive Elements: Regulatory RNA Sequences That Control mRNA Levels and Translation
Casey, J. L., Hentze, M. W., Koeller, D. M., Caughman, S. W., Rouault, T. A., Klausner, R. D., & Harford, J. B. (1988) · Science · doi:10.1126/science.2452485 · Cited by 709
Brain Peroxidase and Catalase in Parkinson Disease
Ambani, L. M., Woert, M. H. V., & Murphy, S. (1975) · Archives of Neurology · doi:10.1001/archneur.1975.00490440064010 · Cited by 404

Show all 29 references

Research works printed but not linked: 4

Barbeau A., 1985, Uneven prevalence of Parkinson's disease in the province of Quebec, Can. J. Neurol. Sci., 12, 169
Barbeau A., 1986, Advances in Neurology, 299
Donaldson J., 1974, Advances in Neurology, 245
Youdim M. B. H., 1985, Handbook of Neurochemisiry, 731

Sorted by citations

Items 201–300 of 1,000

Uric acid is reduced in the substantia nigra in parkinson's disease: Effect on dopamine oxidation
Church, W. H., & Ward, V. L. (1994) · Brain Research Bulletin · doi:10.1016/0361-9230(94)90285-2 · Cited by 154
Contrast mechanisms associated with neuromelanin‐MRI
Trujillo, P., Summers, P. E., Ferrari, E., Zucca, F. A., Sturini, M., Mainardi, L. T., Cerutti, S., Smith, A. K., Smith, S. A., Zecca, L., et al. (2016) · Magnetic Resonance in Medicine · doi:10.1002/mrm.26584 · Cited by 154
Calcium and neuronal injury in Alzheimer's disease. Contributions of beta-amyloid precursor protein mismetabolism, free radicals, and metabolic compromise.
Mattson, M. P. (1994) · PubMed · Cited by 154
Oxidative Stress and Parkinson's Diseasea
Owen, A., Schapira, A. H. V., Jenner, P. G., & MARSDEN, C. D. (1996) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb39064.x · Cited by 154
Self-citation
The molecular and cellular basis of copper dysregulation and its relationship with human pathologies
Maung, M. T., Carlson, A., Olea‐Flores, M., Elkhadragy, L., Schachtschneider, K. M., Navarro‐Tito, N., & Padilla‐Benavides, T. (2021) · The FASEB Journal · doi:10.1096/fj.202100273rr · Cited by 158
Oxygen Free Radicals and Human Diseases
Aruoma, O. I., Kaur, H., & Halliwell, B. B. (1991) · Journal of the Royal Society of Health · doi:10.1177/146642409111100506 · Cited by 152
The art of building multifunctional metal-binding agents from basic molecular scaffolds for the potential application in neurodegenerative diseases
Rodríguez-Rodríguez, C., Telpoukhovskaia, M., & Orvig, C. (2012) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2012.03.008 · Cited by 151
Cerebrospinal fluid levels of transition metals in patients with Parkinson's disease
Jiménez‐Jiménez, F. J., Molina, J. A., Aguilar, M. V., Meseguer, I., Mateos-Vega, C. J., González‐Muñoz, M. J., de Bustos, F., Martínez‐Salio, A., Pareja, M. O., Zurdo, M., et al. (1998) · Journal of Neural Transmission · doi:10.1007/s007020050073 · Cited by 151
Pathogenesis-Targeted, Disease-Modifying Therapies in Parkinson Disease
AlDakheel, A., Kalia, L. V., & Lang, A. E. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0218-1 · Cited by 164
Genetic and Epigenetic Etiology Underlying Autism Spectrum Disorder
Yoon, S. H., Choi, J., Lee, W. Y., & Do, J. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9040966 · Cited by 175
Parkinson's disease: Alterations in iron and redox biology as a key to unlock therapeutic strategies
Ma, L., Azad, M. G., Dharmasivam, M., Richardson, V., Quinn, R. J., Feng, Y., Pountney, D. L., Tonissen, K. F., Mellick, G. D., Yanatori, I., et al. (2021) · Redox Biology · doi:10.1016/j.redox.2021.101896 · Cited by 151
Increased m-calpain expression in the mesencephalon of patients with parkinson's disease but not in other neurodegenerative disorders involving the mesencephalon: a role in nerve cell death?
Prigent, A., Karlsson, J., Agid, Y., & Hirsch, É. C. (1996) · Neuroscience · doi:10.1016/0306-4522(96)00100-5 · Cited by 149
Self-citation
Oxidative and nitrative alpha‐synuclein modifications and proteostatic stress: implications for disease mechanisms and interventions in synucleinopathies
Schildknecht, S., Gerding, H. R., Karreman, C., Drescher, M., Lashuel, H. A., Outeiro, T. F., Di Monte, D. A., & Leist, M. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12226 · Cited by 148
Non-invasive evaluation of nigrostriatal neuropathology in a proteasome inhibitor rodent model of Parkinson's disease
Vernon, A. C., Johansson, S., & Modo, M. (2010) · BMC Neuroscience · doi:10.1186/1471-2202-11-1 · Cited by 147
Laser Ablation–Inductively Coupled Plasma–Mass Spectrometry Imaging in Biology
Doble, P., de Vega, R. G., Bishop, D., Hare, D. J., & Clases, D. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01219 · Cited by 153
Evaluation of Markers of Oxidative Stress, Antioxidant Function and Astrocytic Proliferation in the Striatum and Frontal Cortex of Parkinson’s Disease Brains
Mythri, R. B., Venkateshappa, C., Harish, G., Mahadevan, A., Muthane, U. B., Yasha, T. C., Bharath, M. M. S., & Shankar, S. K. (2011) · Neurochemical Research · doi:10.1007/s11064-011-0471-9 · Cited by 148
PPAR: a therapeutic target in Parkinson’s disease
Chaturvedi, R. K., & Beal, M. F. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05388.x · Cited by 151
The Relationship between Intracellular Free Iron and Cell Injury in Cultured Neurons, Astrocytes, and Oligodendrocytes
Kress, G. J., Dineley, K. E., & Reynolds, I. J. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-14-05848.2002 · Cited by 143
Point mutations of mitochondrial genome in Parkinson's disease
Ikebe, S.-I., Tanaka, M., & Ozawa, T. (1995) · Molecular Brain Research · doi:10.1016/0169-328x(94)00209-w · Cited by 144
Redox status of plasma coenzyme Q10 indicates elevated systemic oxidative stress in Parkinson's disease
Sohmiya, M., Tanaka, M., Wei Tak, N., Yanagisawa, M., Tanino, Y., Suzuki, Y., Okamoto, K., & Yamamoto, Y. (2004) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2004.05.007 · Cited by 143
Hydroxyl Radicals, Iron, Oxidative Stress, and Neurodegenerationa
Gutteridge, J. M. C. (1994) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1994.tb21805.x · Cited by 145
7 tesla magnetic resonance imaging: A closer look at substantia nigra anatomy in Parkinson's disease
Lehéricy, S., Bardinet, É., Poupon, C., Vidailhet, M., & François, C. (2014) · Movement Disorders · doi:10.1002/mds.26043 · Cited by 150
Assessment of brain iron and neuronal integrity in patients with Parkinson's disease using novel MRI contrasts
Michaeli, S., Öz, G., Sorce, D. J., Garwood, M., Uǧurbil, K., Majestic, S., & Tuite, P. (2006) · Movement Disorders · doi:10.1002/mds.21227 · Cited by 141
Astrocyte functions in the copper homeostasis of the brain
Scheiber, I. F., & Dringen, R. (2012) · Neurochemistry International · doi:10.1016/j.neuint.2012.08.017 · Cited by 142
Superoxide dismutase and neurological disorders
Chidambaram, S. B., Anand, N., Varma, S. R., Ramamurthy, S., Vichitra, C., Sharma, A., Mahalakshmi, A. M., & Essa, M. M. (2024) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2023.11.007 · Cited by 162
A review of the use of magnetic resonance imaging in Parkinson’s disease
Pyatigorskaya, N., Galléa, C., García-Lorenzo, D., Vidailhet, M., & Lehéricy, S. (2013) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285613511507 · Cited by 147
Reactive oxygen species generation by the ethylene-bis-dithiocarbamate (EBDC) fungicide mancozeb and its contribution to neuronal toxicity in mesencephalic cells
Domico, L. M., COOPER, K., BERNARD, L., & Zeevalk, G. D. (2007) · NeuroToxicology · doi:10.1016/j.neuro.2007.04.008 · Cited by 139
Unique copper‐induced oligomers mediate alpha‐synuclein toxicity
Wright, J. A., Wang, X., & Brown, D. R. (2009) · The FASEB Journal · doi:10.1096/fj.09-130039 · Cited by 140
Reactive oxygen species and the neurodegenerative disorders.
Knight, J. A. (1997) · PubMed · Cited by 139
Trace and major elements in whole blood, serum, cerebrospinal fluid and urine of patients with Parkinson?s disease
Forte, G., Bocca, B., Senofonte, O., Petrucci, F., Brusa, L., Stanzione, P., Zannino, S., Violante, N., Alimonti, A., & Sancesario, G. (2004) · Journal of Neural Transmission · doi:10.1007/s00702-004-0124-0 · Cited by 138
Calcium and Neuronal Injury in Alzheimer's Disease: Contributions of β‐Amyloid Precursor Protein Mismetabolism, Free Radicals, and Metabolic Compromisea
MATTSON, M. P. (1994) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1994.tb44401.x · Cited by 166
Iron, the substantia nigra and related neurological disorders
Snyder, A. M., & Connor, J. R. (2008) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2008.08.005 · Cited by 138
Evaluation of the Pro-Oxidant and Antioxidant Actions of L-DOPA and Dopamine in Vitro: Implications for Parkinson's Disease
Spencer, J. P. E., Jenner, A. M., Butler, J., Aruoma, O. I., Dexter, D. T., Jenner, P. G., & Halliwell, B. B. (1996) · Free Radical Research · doi:10.3109/10715769609088005 · Cited by 136
Self-citation
Increased Iron in the Substantia Nigra Compacta of the MPTP‐Lesioned Hemiparkinsonian African Green Monkey: Evidence from Proton Microprobe Elemental Microanalysis
Temlett, J. A., Landsberg, J. P., Watt, F., & Orime, G. W. (1994) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1994.62010134.x · Cited by 137
Structure and function of amyloid in Alzheimer's disease
Morgan, C., Colombres, M., Núñez, M. T., & Inestrosa, N. C. (2004) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2004.10.004 · Cited by 146
Carboxyfullerene Prevents Iron‐Induced Oxidative Stress in Rat Brain
Lin, A. M.-Y., Chyi, B. Y., Wang, S. D., Yu, H., Kanakamma, P. P., Luh, T., Chou, C., & Ho, L. T. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.721634.x · Cited by 136
Binding of Iron to Neuromelanin of Human Substantia Nigra and Synthetic Melanin: An Electron Paramagnetic Resonance Spectroscopy Study
Shima, T., Sarna, T., Swartz, H. M., Stroppolo, A., Gerbasi, R., & Zecca, L. (1997) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(96)00623-5 · Cited by 135
MRI evaluation of the basal ganglia size and iron content in patients with Parkinson's disease
Kosta, P., Argyropoulou, M. I., Markoula, S., & Konitsiotis, S. (2005) · Journal of Neurology · doi:10.1007/s00415-005-0914-9 · Cited by 135
Effects of iron deficiency and iron overload on manganese uptake and deposition in the brain and other organs of the rat
Chua, A. C. G., & Morgan, E. H. (1996) · Biological Trace Element Research · doi:10.1007/bf02784167 · Cited by 137
Disrupted iron homeostasis causes dopaminergic neurodegeneration in mice
Matak, P., Matak, A., Moustafa, S. M., Aryal, D. K., Benner, E. J., Wetsel, W. C., & Andrews, N. C. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1519473113 · Cited by 136
Copper dyshomoeostasis in Parkinson's disease: implications for pathogenesis and indications for novel therapeutics
Davies, K. M., Mercer, J. F. B., Chen, N., & Double, K. L. (2016) · Clinical Science · doi:10.1042/cs20150153 · Cited by 139
Mapping metals in Parkinson's and normal brain using rapid-scanning x-ray fluorescence
Popescu, B. F. G., George, M. J., Bergmann, U., Garachtchenko, A., Kelly, M., McCrea, R. P. E., Luening, K., Devon, R. M., George, G. N., Hanson, A. D., et al. (2009) · Physics in Medicine and Biology · doi:10.1088/0031-9155/54/3/012 · Cited by 133
Iron-Mediated Generation of the Neurotoxin 6-Hydroxydopamine Quinone by Reaction of Fatty Acid Hydroperoxides with Dopamine: A Possible Contributory Mechanism for Neuronal Degeneration in Parkinson's Disease
Pezzella, A., d’Ischia, M., Napolitano, A., Misuraca, G., & Prota, G. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm970099t · Cited by 133
Neuromelanin and iron in human locus coeruleus and substantia nigra during aging: consequences for neuronal vulnerability
Zucca, F. A., Bellei, C., Giannelli, S. G., Terreni, M., Gallorini, M., Rizzio, E., Pezzoli, G., Albertini, A., & Zecca, L. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-006-0453-2 · Cited by 132
Iron and Oxidative Stress in Parkinson’s Disease: An Observational Study of Injury Biomarkers
Medeiros, M. S., Schumacher-Schuh, A., Cardoso, A. M., Bochi, G. V., Baldissarelli, J., Kegler, A., Santana, D., Chaves, C. M. M. B. S., Schetinger, M. R. C., Moresco, R. N., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0146129 · Cited by 131
Iron in the Brain: An Important Contributor in Normal and Diseased States
Piñero, D. J., & Connor, J. R. (2000) · The Neuroscientist · doi:10.1177/107385840000600607 · Cited by 132
The role of copper ions in pathophysiology and fluorescent sensors for the detection thereof
Verwilst, P., Sunwoo, K., & Kim, J. S. (2015) · Chemical Communications · doi:10.1039/c4cc10366a · Cited by 133
α-Synuclein and Neuronal Cell Death
Yasuda, T., Nakata, Y., & Mochizuki, H. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8327-0 · Cited by 131
Overexpressing Cu/Zn superoxide dismutase enhances survival of transplanted neurons in a rat model of Parkinson's disease
Nakao, N., Grasbon-Frodl, E. M., Widner, H., Carlson, E. J., Eggerding, F. A., Epstein, C. J., & Brundin, P. (1995) · Nature Medicine · doi:10.1038/nm0395-226 · Cited by 130
Serum trace element levels and the complexity of inter-element relations in patients with Parkinson's disease
Hegde, M. L., Shanmugavelu, P., Vengamma, B., Rao, T. S., Menon, R. B., Rao, R. V., & Rao, K. S. J. (2004) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2004.09.003 · Cited by 129
Neuroprotective role of Withania somnifera root extract in maneb-paraquat induced mouse model of parkinsonism
Prakash, J., Yadav, S. K., Chouhan, S., & Singh, S. P. (2013) · Neurochemical Research · doi:10.1007/s11064-013-1005-4 · Cited by 128
Subcellular compartmentalisation of copper, iron, manganese, and zinc in the Parkinson's disease brain
Genoud, S., Roberts, B. R., Gunn, A. P., Halliday, G. M., Lewis, S. J. G., Ball, H. J., Hare, D. J., & Double, K. L. (2017) · Metallomics · doi:10.1039/c7mt00244k · Cited by 126
Uric acid in Parkinson's disease
Schlesinger, I., & Schlesinger, N. (2008) · Movement Disorders · doi:10.1002/mds.22139 · Cited by 127
Role of metal ions in aggregation of intrinsically disordered proteins in neurodegenerative diseases
Breydo, L., & Uversky, V. N. (2011) · Metallomics · doi:10.1039/c1mt00106j · Cited by 129
Selenoprotein W during development and oxidative stress
Loflin, J., Lopez, N. I., Whanger, P. D., & Kioussi, C. (2006) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2006.05.018 · Cited by 126
Glycoproteomics in neurodegenerative diseases
Hwang, H., Zhang, J., Chung, K. A., Leverenz, J. B., Zabetian, C. P., Peskind, E. R., Jankovic, J. J., Su, Z., Hancock, A. M., Pan, C., et al. (2009) · Mass Spectrometry Reviews · doi:10.1002/mas.20221 · Cited by 125
Iron dysregulation in Huntington's disease
Müller, M., & Leavitt, B. R. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12739 · Cited by 123
Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson?s disease and other neurodegenerative diseases
Youdim, M. B. H., Fridkin, M., & Zheng, H. (2004) · Journal of Neural Transmission · doi:10.1007/s00702-004-0143-x · Cited by 123
Does cellular iron dysregulation play a causative role in Parkinson’s disease?
Kaur, D., & Andersen, J. (2004) · Ageing Research Reviews · doi:10.1016/j.arr.2004.01.003 · Cited by 123
Total and paramagnetic metals in human substantia nigra and its neuromelanin
Zecca, L., & Swartz, H. M. (1993) · Journal of Neural Transmission - Parkinsons Disease and Dementia Section · doi:10.1007/bf02257675 · Cited by 123
Why are nigral catecholaminergic neurons more vulnerable than other cells in Parkinson's disease?
Hirsch, É. C. (1992) · Annals of Neurology · doi:10.1002/ana.410320715 · Cited by 123
Increasing striatal iron content associated with normal aging
Martin, W. R. W., Ye, F. Q., & Allen, P. S. (1998) · Movement Disorders · doi:10.1002/mds.870130214 · Cited by 122
Cellular distribution of the iron-binding protein lactotransferrin in the mesencephalon of Parkinson's disease cases
Leveugle, B., Faucheux, B. A., Bouras, C., Nillesse, N., Spik, G., Hirsch, É. C., Agid, Y., & Hof, P. R. (1996) · Acta Neuropathologica · doi:10.1007/s004010050468 · Cited by 120
Self-citation
Parkinson's disease is associated with oxidative stress: comparison of peripheral antioxidant profiles in living Parkinson's, Alzheimer's and vascular dementia patients
Serra, J. A., Domínguez, R. O., de Lustig, E. S., Guareschi, E. M., Famulari, A. L., Bartolomé, E. L., & Marschoff, E. (2001) · Journal of Neural Transmission · doi:10.1007/s007020170003 · Cited by 119
Role of iron in neurodegenerative diseases
Li, K., & Reichmann, H. (2016) · Journal of Neural Transmission · doi:10.1007/s00702-016-1508-7 · Cited by 121
Binding of α-synuclein with Fe(III) and with Fe(II) and biological implications of the resultant complexes
Peng, Y., Wang, C., Xu, H. H., Liu, Y., & Zhou, F. (2009) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2009.11.005 · Cited by 119
Antioxidant Properties of Bromocriptine, a Dopamine Agonist
Yoshikawa, T., Minamiyama, Y., Naito, Y., & Kondo, M. (1994) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1994.62031034.x · Cited by 118
Copper handling by astrocytes: Insights into neurodegenerative diseases
Tiffany-Castiglioni, E., Hong, S. J., & Qian, Y. (2011) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2011.09.004 · Cited by 116
Parkinson's disease in the nuclear age of neuroinflammation
Nolan, Y. M., Sullivan, A. M., & Toulouse, A. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2012.12.003 · Cited by 119
Mitochondrial iron metabolism and neurodegenerative diseases
Cheng, R., Dhorajia, V. V., Kim, J., & Kim, Y. (2021) · NeuroToxicology · doi:10.1016/j.neuro.2021.11.003 · Cited by 121
Lack of up-regulation of ferritin is associated with sustained iron regulatory protein-1 binding activity in the substantia nigra of patients with Parkinson's disease
Faucheux, B. A., Martin, M., Beaumont, C., Hunot, S., Hauw, J., Agid, Y., & Hirsch, E. C. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01118.x · Cited by 116
Self-citation
Regional brain iron and gene expression provide insights into neurodegeneration in Parkinson’s disease
Thomas, G. E. C., Zarkali, A., Ryten, M., Shmueli, K., Gil-Martínez, A. L., Leyland, L., McColgan, P., Acosta‐Cabronero, J., Lees, A. J., & Weil, R. S. (2021) · Brain · doi:10.1093/brain/awab084 · Cited by 112
The roles of neuromelanin, binding of metal ions, and oxidative cytotoxicity in the pathogenesis of Parkinson's disease: A hypothesis
Enochs, W. S., Sarna, T., Zecca, L., Riley, P. A., & Swartz, H. M. (1994) · Journal of Neural Transmission - Parkinsons Disease and Dementia Section · doi:10.1007/bf02260963 · Cited by 116
Recognition memory impairment and brain oxidative stress induced by postnatal iron administration
de Lima, M. N. M., Polydoro, M., Laranja, D. C., Bonatto, F., Bromberg, E., Moreira, J. C. F., Dal‐Pizzol, F., & Schröder, N. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04083.x · Cited by 119
Enhanced N-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Toxicity in Mice Deficient in CuZn-Superoxide Dismutase or Glutathione Peroxidase
Zhang, J., Graham, D. G., Montine, T. J., & Ho, Y.-S. (2000) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/59.1.53 · Cited by 114
Oxidative and non‐oxidative mechanisms of neuronal cell death and apoptosis by L ‐3,4‐dihydroxyphenylalanine ( L ‐DOPA) and dopamine
Pedrosa, R., & Soares-da-Silva, P. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704982 · Cited by 115
Copper, Ceruloplasmin, Superoxide Dismutase and Iron Parameters in Parkinson's Disease
Tórsdóttir, G., Kristinsson, J., Sveinbjörnsdóttir, S., Snædal, J., & Jøhannesson, T. (1999) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1999.tb02015.x · Cited by 115
Selenium effectively inhibits ROS-mediated apoptotic neural precursor cell death in vitro and in vivo in traumatic brain injury
Yeo, J. E., & Kang, S. K. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2007.09.004 · Cited by 115
Role of heavy metals (copper (Cu), arsenic (As), cadmium (Cd), iron (Fe) and lithium (Li)) induced neurotoxicity
Vellingiri, B., Suriyanarayanan, A., Selvaraj, P., Abraham, K. S., Pasha, M. T., Babu, H. W. S., Gopalakrishnan, A. V., Singaravelu, G., Reddy, J. K., Ayyadurai, N., et al. (2022) · Chemosphere · doi:10.1016/j.chemosphere.2022.134625 · Cited by 114
Research on ferroptosis as a therapeutic target for the treatment of neurodegenerative diseases
Wang, Y., Lv, M.-N., & Zhao, W. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102035 · Cited by 122
Role of brain iron accumulation in cognitive dysfunction: evidence from animal models and human studies
Schröder, N., Figueiredo, L. S., & de Lima, M. N. M. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-121996 · Cited by 113
Antioxidative Effect of Vitamin D3 on Zinc-Induced Oxidative Stress in CNS
Lin, A. M.-Y., CHEN, K. B., & CHAO, P. L. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1344.028 · Cited by 113
FerriBRIGHT: A Rationally Designed Fluorescent Probe for Redox Active Metals
Kennedy, D. P., Kormos, C. M., & Burdette, S. C. (2009) · Journal of the American Chemical Society · doi:10.1021/ja901653u · Cited by 112
Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson's disease
Gerlach, M., Double, K. L., Ben‐Shachar, D., Zecca, L., Youdim, M. B. H., & Riederer, P. F. (2003) · Neurotoxicity Research · doi:10.1007/bf03033371 · Cited by 112
Current Status of Antioxidant Therapy for Alzheimer's Disease
Pitchumoni, S., & Doraiswamy, P. M. (1998) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1998.tb01544.x · Cited by 112
Inhibition of thrombin‐induced microglial activation and NADPH oxidase by minocycline protects dopaminergic neurons in the substantia nigra in vivo
Choi, S. H., Lee, D. Y., Chung, E. S., Hong, Y. B., Kim, S. U., & Jin, B. K. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03503.x · Cited by 112
Reactive Oxygen Species and the Central Nervous System
Halliwell, B. B. (1992) · Springer eBooks · doi:10.1007/978-3-642-77609-0_2 · Cited by 111
Parkinson's disease as multifactorial oxidative neurodegeneration: implications for integrative management.
Kidd, P. M. (2000) · PubMed · Cited by 110
Anti-Oxidants in Parkinson's Disease Therapy: A Critical Point of View
Filograna, R., Beltramini, M., Bubacco, L., & Bisaglia, M. (2016) · Current Neuropharmacology · doi:10.2174/1570159x13666151030102718 · Cited by 110
Neuromelanin magnetic resonance imaging of nigral volume loss in patients with Parkinson’s disease
Kashihara, K., Shinya, T., & Higaki, F. (2011) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2010.08.043 · Cited by 107
Copper- and iron-induced differential fibril formation in α-synuclein: TEM study
..., B., Indi, S. S., & Rao, K. S. J. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2007.06.052 · Cited by 109
Apoptosis: A Key in Neurodegenerative Disorders
Ekshyyan, O. Y., & Aw, T. Y. (2004) · Current Neurovascular Research · doi:10.2174/1567202043362018 · Cited by 110
Nutritional Risk Factors, Microbiota and Parkinson’s Disease: What Is the Current Evidence?
Boulos, C., Yaghi, N., El Hayeck, R., Heraoui, G. N., & Fakhoury-Sayegh, N. (2019) · Nutrients · doi:10.3390/nu11081896 · Cited by 109
Intracellular Chemical Imaging of the Developmental Phases of Human Neuromelanin Using Synchrotron X-ray Microspectroscopy
Bohic, S., Murphy, K., Paulus, W., Cloetens, P., Salome-Pateyron, M., Susini, J., & Double, K. L. (2008) · Analytical Chemistry · doi:10.1021/ac801817k · Cited by 109
Alpha Synuclein Determines Ferroptosis Sensitivity in Dopaminergic Neurons via Modulation of Ether-Phospholipid Membrane Composition
Mahoney‐Sanchez, L., Bouchaoui, H., Boussaad, I., Jonneaux, A., Timmerman, K., Berdeaux, O., Ayton, S., Krüger, R., Duce, J. A., Devos, D., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111231 · Cited by 113
Zingerone [4-(4-hydroxy-3-methoxyphenyl)-2-butanone] Prevents 6-Hydroxydopamine-induced Dopamine Depression in Mouse Striatum and Increases Superoxide Scavenging Activity in Serum
Kabuto, H., Nishizawa, M., Tada, M., Higashio, C., Shishibori, T., & Kohno, M. (2005) · Neurochemical Research · doi:10.1007/s11064-005-2606-3 · Cited by 108
Eugenol [2-Methoxy-4-(2-propenyl)phenol] Prevents 6-Hydroxydopamine-Induced Dopamine Depression and Lipid Peroxidation Inductivity in Mouse Striatum
Kabuto, H., Tada, M., & Kohno, M. (2007) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.30.423 · Cited by 107
Oxidative damage to proteins and lipids of CNS myelin produced by in vitro generated reactive oxygen species
Bongarzone, E. R., Pasquini, J. M., & Soto, E. F. (1995) · Journal of Neuroscience Research · doi:10.1002/jnr.490410209 · Cited by 107
Revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease—resemblance to the effect of amphetamine drugs of abuse
Perfeito, R., Cunha‐Oliveira, T., & Rego, A. C. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.08.569 · Cited by 109
Advances in imaging in Parkinson's disease
Stoessl, A. J., Martin, W. R. W., McKeown, M. J., & Sossi, V. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70214-9 · Cited by 106

Authors: Dexter, D. T., Wells, F. R., Lee, A. J., Agid, F., Agid, Y., Jenner, P., & Marsden, C. D.
Affiliations: King's College London (GB)
National Hospital for Neurology and Neurosurgery (GB)
Inserm (FR)
Corresponding author: Jenner, P.
ORCID: Dexter, D. T.
Jenner, P.
Venue: Journal of Neurochemistry
Publisher: Wiley
Published: 1989-06
Volume: 52
Issue: 6
Pages: 1830-1836
ISSN: 0022-3042 (ISSN-L)
1471-4159
DOI: 10.1111/j.1471-4159.1989.tb07264.x
OpenAlex: W1985613988
Cited by: 1,149
References: 29
Citations by year: 2026: 18 · 2025: 26 · 2024: 31 · 2023: 32 · 2022: 46 · 2021: 42 · 2020: 35 · 2019: 33 · 2018: 35 · 2017: 41 · 2016: 45 · 2015: 21 · 2014: 37 · 2013: 45 · 2012: 41
FWCI: 24.67
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor, 6335 d)
Locations: Journal of Neurochemistry (publishedVersion)
PubMed (publishedVersion)
UCL Discovery (University College London) (submittedVersion)
Topics: Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
Health Sciences › Nursing › Nutrition and Dietetics › Trace Elements in Health
Keywords: Parkinson's disease, substantia nigra, iron, copper, zinc, manganese, lead, globus pallidus, caudate nucleus, putamen, oxidative stress, neurodegeneration
MeSH terms: Aged, Aged, 80 and over, Brain, Female, Humans, Ions, Iron, Male, Metals, Parkinson Disease, Substantia Nigra, Tissue Distribution

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Increased Nigral Iron Content and Alterations in Other Metal Ions Occurring in Brain in Parkinson's Disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks